FDA Approved: SAVAYSA — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

FDA approves a supplemental application for SAVAYSA (edoxaban tosylate) from Daiichi Sankyo, resulting in an update to the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Nonvalvular Atrial Fibrillation
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Savaysa (edoxaban)

Snippet

SUPPL AP for SAVAYSA (EDOXABAN TOSYLATE)